Fmr LLC Has $294.23 Million Stake in Ascendis Pharma A/S (ASND)

Fmr LLC lifted its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 24.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,152,262 shares of the biotechnology company’s stock after purchasing an additional 812,468 shares during the quarter. Fmr LLC owned about 9.88% of Ascendis Pharma A/S worth $294,230,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the company. FIL Ltd grew its stake in Ascendis Pharma A/S by 226.5% during the 3rd quarter. FIL Ltd now owns 113,118 shares of the biotechnology company’s stock valued at $8,016,000 after purchasing an additional 78,474 shares in the last quarter. BlackRock Inc. grew its stake in Ascendis Pharma A/S by 5.1% during the 3rd quarter. BlackRock Inc. now owns 460,961 shares of the biotechnology company’s stock valued at $32,663,000 after purchasing an additional 22,172 shares in the last quarter. Fosun International Ltd acquired a new stake in Ascendis Pharma A/S during the 3rd quarter valued at approximately $3,544,000. PNC Financial Services Group Inc. grew its stake in Ascendis Pharma A/S by 28.5% during the 3rd quarter. PNC Financial Services Group Inc. now owns 6,760 shares of the biotechnology company’s stock valued at $480,000 after purchasing an additional 1,500 shares in the last quarter. Finally, Alliancebernstein L.P. grew its stake in Ascendis Pharma A/S by 2.7% during the 3rd quarter. Alliancebernstein L.P. now owns 714,366 shares of the biotechnology company’s stock valued at $50,620,000 after purchasing an additional 19,039 shares in the last quarter. Institutional investors and hedge funds own 95.60% of the company’s stock.

ASND has been the subject of a number of recent analyst reports. Canaccord Genuity initiated coverage on Ascendis Pharma A/S in a research note on Tuesday, August 7th. They set a “buy” rating and a $81.00 price objective for the company. BidaskClub lowered Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research note on Wednesday, August 8th. Stifel Nicolaus lowered their price objective on Ascendis Pharma A/S from $85.00 to $81.00 and set a “buy” rating for the company in a research note on Thursday, August 30th. Wells Fargo & Co lifted their target price on Ascendis Pharma A/S from $83.00 to $88.00 and gave the stock an “outperform” rating in a research report on Thursday, August 30th. Finally, JPMorgan Chase & Co. lifted their target price on Ascendis Pharma A/S from $79.00 to $81.00 and gave the stock an “overweight” rating in a research report on Thursday, August 30th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Ascendis Pharma A/S has a consensus rating of “Buy” and an average target price of $77.56.

Shares of ASND opened at $67.51 on Monday. Ascendis Pharma A/S has a 52 week low of $35.41 and a 52 week high of $76.99.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Wednesday, November 28th. The biotechnology company reported ($0.94) EPS for the quarter, topping the consensus estimate of ($1.23) by $0.29. The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.16 million. Ascendis Pharma A/S had a negative return on equity of 45.44% and a negative net margin of 38,569.44%. On average, research analysts predict that Ascendis Pharma A/S will post -4.17 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Fmr LLC Has $294.23 Million Stake in Ascendis Pharma A/S (ASND)” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/12/03/fmr-llc-has-294-23-million-stake-in-ascendis-pharma-a-s-asnd.html.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Featured Article: What is a conference call?

Institutional Ownership by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply